Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Richard Oneill

Geriatric Medicine Saint Louis, MO Medical Doctor

NPI 1265570485 CMS profile 239321

11155 Dunn Rd, Suite 202E, Saint Louis, MO 63136

Open in the dashboard

General payments

$1,411

80 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Richard Oneill of Saint Louis, MO is reported in the CMS Open Payments database as having received $1,411 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $106 5
2022 General $291 15
2021 General $329 19
2020 General $379 22
2019 General $306 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Oneill
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Richard Oneill were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Richard Oneill Geriatric Medicine median Middle half National median
2019 $306 $122 $40–$435 $163
2020 $379 $98 $25–$349 $114
2021 $329 $125 $34–$441 $132
2022 $291 $124 $36–$408 $149
2023 $106 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $346 20 payments
  2. Lilly USA, LLC $239 12 payments
  3. Amarin Pharma Inc. $206 12 payments
  4. Allergan Inc. $75 5 payments
  5. Janssen Pharmaceuticals, Inc $69 3 payments
  6. Pfizer Inc. $65 4 payments
  7. AbbVie, Inc. $43 3 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $41 2 payments
  9. E.R. Squibb & Sons, L.L.C. $37 2 payments
  10. Novartis Pharmaceuticals Corporation $34 2 payments
  11. Other $254 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,411 80 payments
Products named General payments · program years 2019–2023
  1. Ozempic $315 18 payments
  2. RYBELSUS $218 12 payments
  3. Vascepa $206 12 payments
  4. JARDIANCE $174 9 payments
  5. TRULICITY $160 8 payments
  6. XARELTO $69 3 payments
  7. MOUNJARO $66 3 payments
  8. NURTEC ODT $56 3 payments
  9. BASAGLAR $55 3 payments
  10. UBRELVY $43 3 payments
  11. Other $600 37 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 138 drugs

Part D claims

8,539

Median for Internal Medicine: 777

Drug cost

$391,728

Median for Internal Medicine: $73,373

Branded share of claims

19.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 65 $72,378
Ozempic Semaglutide Brand 40 $56,515
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $34,559
Jardiance Empagliflozin Brand 30 $32,786
Januvia Sitagliptin Phosphate Brand 16 $24,102
Xarelto Rivaroxaban Brand 19 $16,832
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 303 $8,817
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 20 $8,445
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 136 $5,937
Memantine Hcl Er Memantine Hcl Brand 25 $4,939

The 10 drugs with the highest cost, of 138 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$98,563

Medicare's payments for the services billed

Medicare patients

377

Average age 74

Services billed

1,515

174 women, 203 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 30%
Diabetes 29%
Heart failure 19%
Atrial fibrillation 16%
Chronic kidney disease 16%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record